Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Stem Cell Procurement

Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation

Abstract

Haemopoietic stem cell therapy is an increasingly adopted procedure in the treatment of patients with malignant lymphoma. In this retrospective analysis, we evaluated 262 patients, 57 (22%) with Hodgkin's and 205 (78%) with non-Hodgkin's lymphomas (NHL), and 665 harvesting procedures in order to assess the impact of poor mobilization on survival and to determine the factors that may be predictive of CD34+ poor mobilization. The mobilization chemotherapy regimens consisted of high-dose cyclophosphamide in 92 patients (35.1%) and a high-dose cytarabine-containing regimen (DHAP in 87 patients –(33.2%), MAD in 83 (31.7%)). The incidence of poor mobilizers (<2 × 106 CD34+ cells/kg) was 17.9% overall, with a 10% of very poor mobilizers (1 × 106/kg). Refractory disease status and chemotherapeutic load (>3 regimens) before mobilization played a negative role and were associated with poor mobilization. Survival analysis of all harvested patients showed an overall survival at 3 years of 71% in good mobilizers vs 33% in poor mobilizers (P=0.002). The event-free survival at 3 years was 23% in poor mobilizers and 58% in good mobilizers (P=0.04). We conclude that in NHL patients, poor mobilization status is predictive of survival.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Marcoullis G, Mehta J, Treleaven J . Autologous bone marrow and peripheral blood stem cell transplantation in haematological malignancies: current status. Med Oncol 1995; 12: 209–218.

    Article  CAS  PubMed  Google Scholar 

  2. Strehl J, Mey U, Glasmacher A, Djulbegovic B, Mayr C, Gorschluter M . High-dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non-Hodgkin's lymphoma: a meta-analysis. Haematologica 2003; 88: 1304–1315.

    CAS  PubMed  Google Scholar 

  3. Seropian S, Bahceci E, Cooper DL . Allogeneic peripheral blood stem cell transplantation for high-risk non-Hodgkin's lymphoma. Bone Marrow Transplant 2003; 32: 763–769.

    Article  CAS  PubMed  Google Scholar 

  4. Kewalramani T, Nimer SD, Zelenetz AD, Malhotra S, Qin J, Yahalom J et al. Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant 2003; 32: 673–679.

    Article  CAS  PubMed  Google Scholar 

  5. Lin TS, Copelan EA . Autologous stem cell transplantation for non-Hodgkin's lymphoma. Curr Hematol Rep 2003; 2: 310–315.

    PubMed  Google Scholar 

  6. van Besien K, Loberiza Jr FR, Bajorunaite R, Armitage JO, Bashey A, Burns LJ et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003; 102: 3521–3529.

    Article  CAS  PubMed  Google Scholar 

  7. Nademanee A, Sniecinski I, Schmidt GM, Dagis AC, O'Donnell MR, Snyder DS et al. High dose therapy followed by autologous peripheral blood stem cell transplantation for patients with Hodgkin's disease and non-Hodgkin's Lymphoma using unprimed and granulocyte colony stimulating factor-mobilized peripheral blood stem cells. J Clin Oncol 1994; 12: 2176–2186.

    Article  CAS  PubMed  Google Scholar 

  8. Mahmoud H, Fahmy O, Kamel A, Kamel M, El-Haddad A, El-Kadi D et al. Peripheral blood vs bone marrow as a source for allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 1999; 24: 355–358.

    Article  CAS  PubMed  Google Scholar 

  9. Fauser AA, Basara N, Blau IW, Kiehl MG . A comparative study of peripheral blood stem cell vs bone marrow transplantation from unrelated donors (MUD): a single center study. Bone Marrow Transplant 2000; 25 (Suppl 2): S27–S31.

    Article  PubMed  Google Scholar 

  10. Kanteti R, Miller K, McCann J, Roitman D, Morelli J, Hurley C et al. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis. Bone Marrow Transplant 1999; 24: 473–481.

    Article  CAS  PubMed  Google Scholar 

  11. Majolino I, Pearce R, Taghipour G, Goldstone AH . Peripheral-blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin's and non-Hodgkin's lymphomas: a new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry Data. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 1997; 15: 509–517.

    Article  CAS  PubMed  Google Scholar 

  12. Kessinger A, Vose JM, Bierman PJ, Bishop M, Armitage JO . Peripheral stem cell transplantation in non-Hodgkin's lymphoma patients. J Hematother 1993; 2: 361–362.

    Article  CAS  PubMed  Google Scholar 

  13. Cottler-Fox MH, Lapidot T, Petit I, Kollet O, DiPersio JF, Link D et al. Stem cell mobilization. Hematology (Am Soc Hematol Educ Program) 2003, 419–437.

    Article  Google Scholar 

  14. Pavone V, Gaudio F, Guarini A, Perrone T, Zonno A, Curci P et al. Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma. Bone Marrow Transplant 2002; 29: 285–290.

    Article  CAS  PubMed  Google Scholar 

  15. Russell NH, McQuaker G, Stainer C, Byrne JL, Haynes AP . Stem cell mobilisation in lymphoproliferative diseases. Bone Marrow Transplant 1998; 22: 935–940.

    Article  CAS  PubMed  Google Scholar 

  16. Gianni AM, Siena S, Bregni M, Tarella C, Stern AC, Pileri A et al. Granulocyte–macrophage-colony-stimulating factor to harvest circulating hemopoietic stem cells for autotransplantation. Lancet 1989; 2: 580–585.

    Article  CAS  PubMed  Google Scholar 

  17. Perez-Simon JA, Martin A, Caballero D, Corral M, Nieto MJ, Gonzalez M et al. Clinical significance of CD34+ cell dose in long-term engraftment following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1999; 24: 1279–1283.

    Article  CAS  PubMed  Google Scholar 

  18. Bensinger WI, Longin K, Appelbaum F, Rowley S, Weaver C, Lilleby K et al. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factors (rhGCSF): an analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 1994; 87: 825–831.

    Article  CAS  PubMed  Google Scholar 

  19. Weaver CH, Potz J, Redmond J, Tauer K, Schwartzberg LS, Kaywin P et al. Engraftment and outcome of patients receiving myeloablative therapy followed by autologous peripheral blood stem cells with a low CD34+ cell content. Bone marrow Transplant 1997; 19: 1103–1110.

    Article  CAS  PubMed  Google Scholar 

  20. Sohn SK, Kim JG, Sung WJ, Kim DH, Suh JS, Lee KS et al. Large-volume leukapheresis using femoral venous access for harvesting peripheral blood stem cells with the Fenwal CS 3000 Plus from normal healthy donors: predictors of CD34+ cell yield and collection efficiency. J Clin Apheresis 2003; 18: 10–15.

    Article  PubMed  Google Scholar 

  21. Elliott C, Samson DM, Armitage S, Lyttelton MP, McGuigan D, Hargreaves R et al. When to harvest peripheral-blood stem cells after mobilization therapy: prediction of CD34-positive cell yield by preceding day CD34-positive concentration in peripheral blood. J Clin Oncol 1996; 14: 970–973.

    Article  CAS  PubMed  Google Scholar 

  22. Weaver CH, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961–3969.

    CAS  PubMed  Google Scholar 

  23. Ketterer N, Salles G, Raba M, Espinouse D, Sonet A, Tremisi P et al. High CD34+ cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood 1998; 91: 3148–3155.

    CAS  PubMed  Google Scholar 

  24. Siena S, Bregni M, Brando B, Ravagnani F, Bonadonna G, Gianni AM . Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: enhancement by intravenous recombinant human granulocyte–macrophage colony-stimulating factor. Blood 1989; 74: 1905–1914.

    CAS  PubMed  Google Scholar 

  25. Moskowitz CH, Glassman JR, Wuest D, Maslak P, Reich L, Gucciardo A et al. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma. Clin Cancer Res 1998; 4: 311–316.

    CAS  PubMed  Google Scholar 

  26. Ketterer N, Salles G, Moullet I, Dumontet C, ElJaafari-Corbin A, Tremisi P et al. Factors associated with successful mobilisation of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. Br J Haematol 1998; 103: 235–242.

    Article  CAS  PubMed  Google Scholar 

  27. Haas R, Mohle R, Fruhauf S, Goldschmidt H, Witt B, Flentje M et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83: 3787–3794.

    CAS  PubMed  Google Scholar 

  28. Brown RA, Adkins D, Goodnough LT, Haug JS, Todd G, Wehde M et al. Factors that influence the collection and the engraftment of allogenic peripheral blood stem cells in patients with hematological malignancies. J Clin Oncol 1997; 15: 3067–3074.

    Article  CAS  PubMed  Google Scholar 

  29. Micallef IN, Apostolidis J, Rohatiner AZ, Wiggins C, Crawley CR, Foran JM et al. Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma. Hematol J 2000; 1: 367–373.

    Article  CAS  PubMed  Google Scholar 

  30. Gandhi MK, Jestice K, Scott MA, Bloxham D, Bass G, Marcus RE . The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients. Bone Marrow Transplant 1999; 23: 9–13.

    Article  CAS  PubMed  Google Scholar 

  31. Drake M, Ranaghan L, Morris TC, Nolan L, Desai ZR, Irvine AE et al. Analysis of the effect of prior therapy on progenitor cell yield: use of chemotherapy scoring system. Br J Haematol 1997; 99: 479.

    Google Scholar 

  32. Perry AR, Watts MJ, Peniket AJ, Goldstone AH, Linch DC . Progenitor cell yields are frequently poor in patients with histologicaly indolent lymphomas especially when mobilised within 6 months of previous chemotherapy. Bone Marrow Transplant 1998; 21: 1201–1205.

    Article  CAS  PubMed  Google Scholar 

  33. Schots R, Van Riet I, Damiaens S, Flament J, Lacor P, Staelens Y et al. The absolute number of CD34+ cells predicts the number of hematopoietic stem cells that can be predicted by apheresis. Bone Marrow Transplant 1996; 17: 509–515.

    CAS  PubMed  Google Scholar 

  34. Tarella C, Di Nicola M, Caracciolo D, Zallio F, Cuttica A, Omede P et al. High dose ARA-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilizaton. Bone Marrow Transplant 2002; 30: 725–732.

    Article  CAS  PubMed  Google Scholar 

  35. Benekli M, Hahn T, Shafi F, Qureshi A, Alam AR, Czuczman MS et al. Effect of rituximab on peripheral blood stem cell mobilization and engraftment kinetics in non-Hodgkin's lymphoma patients. Bone Marrow Transplant 2003; 32: 139–143.

    Article  CAS  PubMed  Google Scholar 

  36. Endo T, Sato N, Mogi Y, Koizumi K, Nishio M, Fujimoto K et al. Peripheral blood stem cell mobilization following CHOP plus rituximab therapy combined with G-CSF in patients with B-cell non-Hodgkin's lymphoma. Bone Marrow Transplant 2004; 33: 703–707.

    Article  CAS  PubMed  Google Scholar 

  37. Gordan LN, Sugrue MW, Lynch JW, Williams KD, Khan SA, Wingard JR et al. Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymphoma 2003; 44: 815–820.

    Article  CAS  PubMed  Google Scholar 

  38. Stockerl-Goldstein KE, Reddy SA, Horning SF, Blume KG, Chao NF, Hu WW et al. Favorable outcome in non-Hodgkin's lymphoma patients with ‘poor’ mobilization of peripheral blood progenitor cells. Biol Blood Transplant 2000; 6: 506–512.

    Article  CAS  Google Scholar 

  39. Mavroudis D, Read E, Cottler-Fox M, Couriel D, Molldrem J, Carter C et al. CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies. Blood 1996; 88: 3223–3229.

    CAS  PubMed  Google Scholar 

  40. Stewart DA, Guo D, Luider J, Auer I, Klassen J, Morris D et al. A low CD34+ cell dose predicts relapse and death early following autologous blood stem cell transplantation. Hematology 2001; 6: 19–27.

    Article  CAS  PubMed  Google Scholar 

  41. Barrett JA, Ringden O, Zhang M-J, Bashey A, Cahn JY, Cairo MS et al. Effect of nucleated marrow cell dose on relapse and survival in identical twin transplants for leukemia. Blood 2000; 95: 3323–3327.

    CAS  PubMed  Google Scholar 

  42. Carlo-Stella C, Di Nicola M, Milani R, Guidetti A, Magni M, Milanesi M et al. Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and collection of CD34+ cells in poor mobilizers. Blood 2004; 103: 3287–3295.

    Article  CAS  PubMed  Google Scholar 

  43. Flomenberg N, Devine SM, Dipersio JF, Liesveld JL, McCarty JM, Rowley SD et al. The use of AMD3100 plus G-CSF for autologous hemopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005; 106: 1867–1874.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to V Pavone.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pavone, V., Gaudio, F., Console, G. et al. Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation. Bone Marrow Transplant 37, 719–724 (2006). https://doi.org/10.1038/sj.bmt.1705298

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705298

Keywords

This article is cited by

Search

Quick links